Fitbit launched a large-scale study to validate its technology to detect atrial fibrillation

Fitbit | May 07, 2020

  • Fitbit launched a sweeping heart study on Wednesday aimed at exploring whether its devices can detect atrial fibrillation.

  • The company's focus on health care, along with its work in clinical trials to alert users to conditions like hypertension and sleep apnea.

  • Fitbit's strategy is to make easy-to-use health tools that detect a range of conditions more accessible to the general population.


Wearables giant Fitbit launched a sweeping heart study on Wednesday aimed at exploring whether its devices can detect atrial fibrillation.

It's part of Fitbit's broader ambitions in healthcare to use its wearable technology for preventive health to reduce the risk of life-threatening events like stroke by detecting problems earlier.

With the launch of the heart study, Fitbit is chasing down competitor Apple which received FDA clearance in 2018 for its ECG feature and more recently launched a study with Johnson & Johnson to explore whether its own wearables can detect Afib.

"Wearable data and the kinds of information wearable data can provide will serve as another tier in the healthcare system," Eric Friedman, Fitbit co-founder and chief technology officer told FierceHealthcare.


Read More: DOXIMITY LAUNCHES DOXIMITY DIALER VIDEO- A FREE TELEHEALTH APP FOR PROVIDERS
 

The company's focus on health care, along with its work in clinical trials to alert users to conditions like hypertension and sleep apnea, makes it clear that it wants to pivot its wearables from just fun accessories to health devices. Fitbit’s user-generated health data, combined with the company’s analytics, can provide an "early warning sign" to users about potential problems like irregular heart rhythms suggestive of atrial fibrillation (Afib), Friedman said.

"It could serve as a 'check engine light' to help get that person to the appropriate level of care, and that could be, at first, a telehealth physician or a personal health coach. That's another layer in the healthcare system. Fitbit devices will be a "Minute Clinic' on your wrist before you have to go see a physician," he said.

Fitbit's strategy is to make easy-to-use health tools that detect a range of conditions more accessible to the general population, according to the company.


Until recently, tools for detecting AFib had a number of limitations and were only accessible if you visited a doctor, My hope is that advancing research on innovative and accessible technology, like Fitbit devices, will lead to more tools that help improve health outcomes and reduce the impact of AFib on a large scale.

- Steven Lubitz, M.D., principal investigator of the Fitbit Heart Study


Fitbit launched in 2007 and now has close to 30 million active users. In November, tech giant Google announced plans to buy the company for $2.1 billion, but that deal still needs to be approved by regulators.

Scripps Research Institute and Stanford Medicine are collaborating with Fitbit on research aimed at using Fitbit data to help detect, track and contain infectious diseases like COVID-19.

The two studies are examples of where Fitbit can fit in healthcare, Friedman said.

The heart study looks at individual wearable data to detect heart health trends and the second study looks at population-level wearable data—including heart rate, sleep, and activity levels—to try to detect the early onset of a virus.

"We're not trying to replace the healthcare system. Doctors and clinicians are dealing with acute healthcare issues and they don't have the bandwidth to look at longitudinal trends," Friedman said. "Where Fitbit wants to play and where we have value is that all-day, continuous health monitoring and guidance to help users stay healthy and manage their health conditions."


Focus on heart health
 

The Fitbit Heart Study aims to enroll hundreds of thousands of people, and its results will support the company’s regulatory submissions globally.

To track heart rate, Fitbit’s devices use photoplethysmography (PPG) technology to measure the rate of blood flow directly from a user’s wrist. Theoretically, these measurements can be used to determine a user’s heart rhythm, which Fitbit’s algorithm will analyze for irregularities in the Fitbit Heart Study.

Study participants who receive a notification about an irregular heart rhythm will be connected with a doctor for a virtual appointment at no cost and may receive a free electrocardiogram (ECG) patch in the mail to confirm the notification.

One of the goals of the study is to understand how wearable data and virtual care can be used as a model of healthcare that does not involve in-person care, according to Tony Faranesh, senior research scientist at Fitbit.


This model of care can be used to both offload the in-person care so the healthcare system can focus on more complicated, more acute health issues, and it's also a way of empowering and educating users about their own health and enabling them to make positive changes before they see a doctor.

- Tony Faranesh, senior research scientist at Fitbit.


AFib affects nearly 33.5 million people globally and patients with Afib have five times higher risk of stroke. But it also can be difficult to detect.

Fitbit wearables have the potential to accelerate Afib detection because the devices provide 24/7 heart rate tracking. This enables long-term heart rhythm assessment, including when users are asleep. The optimal way to identify irregular rhythm through heart rate tracking technology is to screen when the body is at rest, according to the company.

"We have the opportunity to develop and provide access to technology that may be able to improve public health and save lives," Friedman said.

Fitbit also is pursuing approval from the U.S. Food and Drug Administration and other global regulatory authorities for its Afib detection software.
 

Read More: HOSPITAL AND PROVIDER GROUPS CHEER NEW CMS FLEXIBILITY ON TELEHEALTH, CAPACITY AND ACO LOSSES
 

Fitbit inked a multiyear partnership with pharmaceutical giants Bristol Myers Squibb and Pfizer last year to develop programs to identify and support people found to be at increased risk for stroke. Those programs will be implemented following FDA clearance for Fitbit's Afib detection software.

Fitbit completed a clinical trial of its new ECG feature for spot detection of AFib and plans to seek review by the FDA and global regulatory authorities.
 

About Fitbit

We're a passionate team dedicated to health and fitness who are building products that help transform people's lives. While health can be serious business, we feel it doesn't have to be. We believe you're more likely to reach your goals if you're encouraged to have fun, smile, and feel empowered along the way.

Spotlight

In the last year the AHIMA Board of Directors undertook the challenge of developing a new view of Health Information Management (HIM)—one that addressed changing practice roles, settings, and functions emerging from increased automation, changing regulations, and dissemination of data.


Other News
AI

Faisal Belhoul joins forces with iGan Partners to launch US$250 million iGan Arabia fund to drive MedTech innovation in MENA

iGan Partners | February 08, 2022

iGan Partners,Canada'sleading healthcare technology investors, has joined forces with Faisal Belhoul, aDubai-based investments professional and entrepreneur, to launch aUS$250MiGan Arabia regional fundto drive MedTech innovation across theMiddle EastandNorth Africaregion. iGan Arabia will focus on investing in AI/Cloud-enhanced medical devices and digital health technologies that improve patient outcomes and reduce healthcare cost. The fund targetsUS$250Mthrough limited partnerships with an additionalUS$250Min co-investments. The first four investments have been identified to drive breakthrough MedTech in the region. These areExact Imaging, the world's first micro-ultrasound for unmatched resolution of prostate cancer;Okadoc, the region's most advanced digital patient management solution;eSight Corporation, wearable electronic vision devices for legally blind people challenged by eye diseases; andMolecuLight, the world's first handheld imaging device enabling clinicians to visualize bacteria in real-time for advanced wound care. All these already have regulatory approval and are scaling world-wide. H.E.Jean-Philippe Linteau, Consul General ofCanadainDubaiand the Northern Emirates, commented: "I am pleased to see Canadian and UAE health innovation leaders partner together to create iGan Arabia. The UAE has proven to be an early adopter of innovation. This new partnership will help our healthcare technology companies grow and succeed globally." "We see the GCC as a transformative healthcare region. We have identified and uncovered several innovative opportunities across Digital Health, Connected Medical Devices, Healthcare IT and Artificial Intelligence. These are sectors that iGan brings a lot of expertise and we understand what it takes for companies to scale and succeed. Through this first of its kind Fund, we will invest locally and will showcase the GCC's healthcare innovations to the world." Sam Ifergan, Founder & CEO, iGan Partners Faisal Belhoul, Co-Chairman, iGan Arabia,added: "Through iGan Arabia we aim to invest in start-ups and other healthcare companies, especially in the GCC, and help them evolve as the best-in-class. We will support not only their operations in the region but also help scale up their operations to key markets inNorth America,Europe, and LATAM. iGan Arabia will help establish GCC as a world-class MedTech hub that will create thousands of new jobs and add value to the economy."

Read More

DIGITAL HEALTHCARE

Habersham Medical Center first hospital in Georgia to adopt digital diagnostic image-sharing platform, PocketHealth

PocketHealth | June 18, 2022

Habersham Medical Center (HMC) announced that it will engage PocketHealth to help make it much easier for the hospital's 80,000 patients to access, share and store their medical imaging and reports securely on any device, enabling them to be more informed and active in their own healthcare journeys. Patients will no longer need to travel to the healthcare facility to collect a CD-ROM of their records and transport it to their next appointment or hope that their critical health information makes it safely to their primary care physician. With PocketHealth, HMC's patients will be able to actively engage in their own healthcare journey by accessing and sharing their imaging reports with their physicians, caregivers, or family members from any device, anywhere in the world. Physicians and other healthcare professionals who share and receive diagnostic images with Habersham will be able to work within the medical center's existing infrastructure and won't need to worry about additional software or account setup. They will be able to view patient imaging instantly in full diagnostic quality or import those images into their local PACS for diagnosis. "We are very excited to make the healthcare experience much easier than it has been for patients at Habersham Medical Center, and in implementing PocketHealth at our hospital, we are equipping patients to be participants in their own medical journey. Until now, when medical imaging and reports were shared it required our patients to make unnecessary trips to the site. Tyler Williams, President, and CEO of Habersham Medical Center PocketHealth equips healthcare providers with the most efficient and effective way to share medical imaging while bringing patients into the center of the process, fueling better outcomes through direct access to diagnostic imaging and reports. Patients can now request all of their imaging records from HMC on the PocketHealth website and gain better insights into their reports with PocketHealth's Report Reader functionality, which breaks down and defines complex medical terms found within radiology reports. "Diagnostic Imaging is essential to understanding a treatment course or for soliciting second opinions and can often be the spark for a long-term care journey," said Rishi Nayyar, co-founder and CEO, PocketHealth. "PocketHealth is thrilled to work with Habersham Medical Center to make it easy for patients and care providers to move through an image-based journey without the unnecessary frustration that often comes with records release and CD-ROM hardware." Habersham Medical Center is focused on serving its communities by providing high quality healthcare to its patients and clinical partnerships. The Center conducts approximately 125,000 imaging exams each year. About PocketHealth PocketHealth is the world's first patient-centric image sharing platform. With PocketHealth, patients can instantly access, share and take ownership over their own medical imaging and records - anytime, anywhere, and with anyone. PocketHealth also enables direct sharing between hospitals and physicians, as well as instant DICOM retrieval and automated importing capability, creating a unified image management solution for more than 600 hospitals and imaging clinics across North America. PocketHealth believes that by placing patients at the center of their care journey, records move more ethically, easily and securely throughout the healthcare system. About Habersham Medical Center Serving over 80,000 residents across northeast Georgia, Habersham Medical Center (HMC) is a 53 licensed-bed, acute care hospital delivering exceptional care and service. As a substantial economic partner for Habersham County, HMC operates three physician practices, a comprehensive rehabilitation program, an 84 licensed-bed, skilled nursing home and the area's only hospital-based, home health service.

Read More

HEALTH TECHNOLOGY

CareView Communications Selected to Exhibit Patient Safety System at Vizient Innovative Technology Exchange

CareView Communications, Inc. | June 22, 2022

CareView Communications, Inc. an information technology provider to the healthcare industry, has been selected to exhibit the CareView Patient Safety System®, including its patented, predictive Virtual Bed Rails® and Virtual Chair Rails® technology, at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17 at the Renaissance, Dallas. The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on its supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety, or drives incremental improvements to health care delivery or business models. The CareView Patient Safety System leverages CareView’s patented Virtual Bed Rails and Virtual Chair Rails, which use machine learning to differentiate between normal patient movements and behaviors of an at-risk patient. Exclusive integrations with the health system’s electronic health record (EHR) and nurse communication systems allow for enhanced clinical workflows and improved response times. With CareView’s system, one staff member can safely monitor and interact with up to 40 patients, resulting in fewer false alarms, quicker staff interventions, and a significant reduction in patient falls. “We are very excited to bring our CareView Patient Safety System to the Vizient Innovative Technology Exchange. CareView’s latest equipment will address hospital staffing shortages, ease care burdens, and improve care efficiency by having a virtual sitter in every at-risk and high acuity patient room.” Sandra McRee, CareView’s Chief Operating Officer “Suppliers come to the Exchange hoping to be awarded an Innovative Technology contract, which signals health care providers of their product’s unique qualities,” said Kelly Flaharty, director of contract process, Vizient. “We are pleased to include CareView’s technology in the group selected to participate.” The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program. About CareView Communications, Inc. As a leader in turnkey patient video monitoring solutions, CareView is redefining the standard of patient safety in hospitals and healthcare facilities across the country. For over a decade, CareView has relentlessly pursued innovative ways to increase patient protection, providing next generation solutions that lower operational costs and foster a culture of safety among patient, staff and hospital leadership. With installations in more than 150 hospitals, CareView has proven that its innovative technology is creating a culture of patient safety where patient falls have decreased by 80% with sitter costs reduced by more than 65%. Anchored by the CareView Patient Safety System, this modular, scalable solution delivers flexible configurations to fit any facility while significantly increasing patient safety and operational savings. All configurations feature HD cameras, high-fidelity 2-way audio/video, LCD displays for the ultimate in capability, flexibility, and affordability. Corporate offices are located at 405 State Highway 121 Bypass, Suite B-240, Lewisville, TX 75067.

Read More

DIGITAL HEALTHCARE

Revibe Technologies Announces Clinical Development Updates for its Investigational FokusRx Prescription Digital Therapy for the Treatment of ADHD

Revibe technologies | February 09, 2022

Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining the efficacy of FokusRx in school aged children with attention deficit hyperactivity disorder (ADHD). FokusRx is an investigational SaMD (Software as a Medical Device) that has the potential to provide a new nonpharmacologic approach to treating attention, focus and hyperactivity deficits associated with ADHD, and other mental health conditions. ADHD is one of the most commonly diagnosed and increasingly prevalent mental health disorders in children and adolescents.Inthe United States, 6.1 million children aged 2-17 years have been diagnosed with ADHD. Approximately 50% of families stop using prescription drug treatments for ADHD within a year.Over 30% of parents refuse pharmacologic treatment for their children with ADHD. In this, single-arm multi-rater feasibility study, parents (n= 38) and teachers (n= 26) rated youth aged 8-12 years with a parent-reported diagnosis of ADHD. Youth were attending in-person classroom learning and not taking medication for their ADHD. The study included a number of outcome measures including the ADHD-RS-5 (Home and School versions), Conners 4 – short version, Weiss Functional Impairment Rating Scale-Parent Form (WFIRS-P), and the Academic Performance Rating Scale (APRS). To be included in the analyses, youth had to have worn the Revibe Connect wearable device to school Monday to Friday for a at least three days per week or a minimum of 15 days total for a period of four weeks. "We are pleased that the feasibility study has proven to be a successful exercise that de-risks our upcoming randomized sham-controlled pivotal trial. The moderate to large effect sizes observed and change scores that exceed standards for minimally important (clinically significant) differences, provide encouraging preliminary evidence supporting the efficacy of our intervention", says Dr.Lindsay Ayearst, Chief Scientific Officer of Revibe. Revibe's Scientific and Medical Advisory Board member, Dr.Margaret Weiss, Director of Clinical Research in Child Psychiatry at Cambridge Health Alliance, stated, "These results are consistent across both symptoms and functioning, and across informants.They would translate into clinically significant change. Most impressive is the demonstration of an effect on academic performance." "The data from the classroom feasibility study suggests FokusRx can effectively and safely improve ADHD symptoms and functioning in school-aged children. It is our intention that FokusRx will provide kids and parents another option to help them succeed and reach their full potential. We are excited to begin designing our pivotal trial planned for the fall." Joseph Koziak, Chief Executive Officer of Revibe About FokusRx FokusRx is an investigational SaMD designed to provide a new nonpharmacologic approach to treating symptoms and impairment associated with ADHD. The FokusRx software is embedded within a dedicated smart watch to act as a digital therapeutic wearable. About Revibe Technologies Revibe Technologies is passionate about leveraging technology to help children and adults with focus and attention problems overcome obstacles in order to succeed in life. Revibe Technologies hopes to be a resource for students, parents, teachers, schools, and clinicians.

Read More

Spotlight

In the last year the AHIMA Board of Directors undertook the challenge of developing a new view of Health Information Management (HIM)—one that addressed changing practice roles, settings, and functions emerging from increased automation, changing regulations, and dissemination of data.

Resources